KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) EBITDA Margin: 2010-2025

Historic EBITDA Margin for Novavax (NVAX) over the last 16 years, with Sep 2025 value amounting to -252.70%.

  • Novavax's EBITDA Margin fell 9413.00% to -252.70% in Q3 2025 from the same period last year, while for Sep 2025 it was 30.74%, marking a year-over-year increase of 6479.00%. This contributed to the annual value of -36.49% for FY2024, which is 2110.00% up from last year.
  • According to the latest figures from Q3 2025, Novavax's EBITDA Margin is -252.70%, which was down 537.55% from 57.75% recorded in Q2 2025.
  • Novavax's EBITDA Margin's 5-year high stood at 77.33% during Q1 2025, with a 5-year trough of -386.37% in Q1 2023.
  • For the 3-year period, Novavax's EBITDA Margin averaged around -94.88%, with its median value being -67.19% (2023).
  • Its EBITDA Margin has fluctuated over the past 5 years, first spiked by 63,138bps in 2021, then slumped by 41,610bps in 2023.
  • Quarterly analysis of 5 years shows Novavax's EBITDA Margin stood at -371.27% in 2021, then surged by 30,304bps to -68.24% in 2022, then spiked by 523bps to -63.01% in 2023, then slumped by 8,542bps to -148.43% in 2024, then tumbled by 9,413bps to -252.70% in 2025.
  • Its EBITDA Margin stands at -252.70% for Q3 2025, versus 57.75% for Q2 2025 and 77.33% for Q1 2025.